GlobeNewswire Inc.··NaIN8bio to Unveil Gamma-Delta T Cell Advances at May R&D Day
IN8bio showcases gamma-delta T cell advances and glioblastoma survival data at May 2026 R&D Day and major medical conferences.
INABclinical dataautoimmune diseases
clinical data
13 articlesGlobeNewswire Inc.··NaGlobeNewswire Inc.··U.S. Food And Drug AdministrationFDA Moves to Revolutionize Drug Development With Real-Time Clinical Trial Data
FDA launches real-time clinical trial initiative with $AMGN and $AZN pilots, aiming to accelerate drug approvals and eliminate traditional reporting delays.
AMGNAZNclinical datadrug development
GlobeNewswire Inc.··NaNovo Nordisk Showcases Obesity Portfolio at European Congress With Wegovy Data, CagriSema Focus
Novo Nordisk will present 52 abstracts on Wegovy and experimental CagriSema at European obesity congress, highlighting cardiovascular benefits and women's health data.
NVOclinical dataweight loss
GlobeNewswire Inc.··Mediwound Ltd.MediWound to Showcase EscharEx Data at Major Conferences as Phase III Trial Expands
MediWound to present new EscharEx clinical and preclinical data at major wound care conferences in April-May 2026, advancing Phase III trial progress and supporting expansion into new indications.
MDWDclinical dataPhase III trial
GlobeNewswire Inc.··Hagens BermanCorcept Therapeutics Hit With Securities Lawsuit Over FDA Rejection and Patent Loss
Hagens Berman files class action against $CORT over alleged concealment of FDA warnings. Stock plunged 50% after December rejection, erasing $2.5B in market value.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.··Hagens BermanCorcept Faces Securities Lawsuit After FDA Rejection, $2.5B Market Wipeout
Hagens Berman sues $CORT over alleged concealment of FDA warnings on relacorilant. Stock crashed 50% following Complete Response Letter, erasing $2.5B in market value.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.··Hagens BermanCorcept Stock Crashes 50% After FDA Rejection and Patent Loss Spark Securities Lawsuit
Hagens Berman files securities class action against $CORT after FDA rejection of lead drug and federal court patent loss, alleging concealment of clinical data warnings.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.··NaZymeworks to Showcase Pipeline Progress at Major Healthcare Conferences
Zymeworks will present clinical and preclinical data at two major healthcare investor conferences in April, including the Needham Virtual Healthcare Conference and Bloom Burton & Co. event.
ZYMEclinical datainvestor conference
The Motley Fool··Eric VolkmanJPMorgan Lifts Edgewise Therapeutics on Pipeline Optimism, Stock Surges
JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.
AMJBJPMJPMpCJPMpDJPMpJ+5clinical databiotech
GlobeNewswire Inc.··Hagens BermanCorcept Faces Securities Lawsuit Over Relacorilant Claims as FDA Rejection Triggers 50% Stock Decline
Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.··NaAquestive to Disclose Q4 2025 Results and Pipeline Progress on March 4-5
Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.
AQSTclinical dataearnings report
GlobeNewswire Inc.··NaAquestive to Unveil Anaphylm Clinical Results at 2026 Allergy Conference
Aquestive to present clinical trial data for Anaphylm, an investigational oral anaphylaxis treatment, at 2026 allergy conference, showing promising safety and efficacy results.
AQSTclinical dataFDA approval
Benzinga··Vandana SinghMerck Partners With Mayo Clinic on AI-Driven Drug Discovery Initiative
Merck partners with Mayo Clinic to use AI and advanced analytics for drug discovery, focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis treatment development.
MRKclinical datastrategic partnership